CN113125719A - 6 antibody kit for monitoring human immune state and application - Google Patents
6 antibody kit for monitoring human immune state and application Download PDFInfo
- Publication number
- CN113125719A CN113125719A CN202110413978.0A CN202110413978A CN113125719A CN 113125719 A CN113125719 A CN 113125719A CN 202110413978 A CN202110413978 A CN 202110413978A CN 113125719 A CN113125719 A CN 113125719A
- Authority
- CN
- China
- Prior art keywords
- sample
- cells
- horizon
- kit
- immune
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000012544 monitoring process Methods 0.000 title claims abstract description 26
- 238000001514 detection method Methods 0.000 claims abstract description 57
- 210000005259 peripheral blood Anatomy 0.000 claims abstract description 29
- 239000011886 peripheral blood Substances 0.000 claims abstract description 29
- 229910052751 metal Inorganic materials 0.000 claims abstract description 23
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims abstract description 18
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 claims abstract description 18
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 claims abstract description 18
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims abstract description 18
- 101000716102 Homo sapiens T-cell surface glycoprotein CD4 Proteins 0.000 claims abstract description 18
- 101000946843 Homo sapiens T-cell surface glycoprotein CD8 alpha chain Proteins 0.000 claims abstract description 18
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 claims abstract description 18
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 claims abstract description 18
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 claims abstract description 16
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 claims abstract description 16
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 claims abstract description 16
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 claims abstract description 15
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 claims abstract description 15
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 claims abstract description 13
- 210000002865 immune cell Anatomy 0.000 claims abstract description 11
- 239000003153 chemical reaction reagent Substances 0.000 claims description 43
- -1 112Cd Chemical compound 0.000 claims description 36
- 210000004027 cell Anatomy 0.000 claims description 31
- 238000002360 preparation method Methods 0.000 claims description 26
- 239000006228 supernatant Substances 0.000 claims description 18
- 239000002184 metal Substances 0.000 claims description 16
- 238000000034 method Methods 0.000 claims description 14
- 239000000872 buffer Substances 0.000 claims description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 12
- 238000001943 fluorescence-activated cell sorting Methods 0.000 claims description 9
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 6
- JLDSMZIBHYTPPR-UHFFFAOYSA-N Alexa Fluor 405 Chemical compound CC[NH+](CC)CC.CC[NH+](CC)CC.CC[NH+](CC)CC.C12=C3C=4C=CC2=C(S([O-])(=O)=O)C=C(S([O-])(=O)=O)C1=CC=C3C(S(=O)(=O)[O-])=CC=4OCC(=O)N(CC1)CCC1C(=O)ON1C(=O)CCC1=O JLDSMZIBHYTPPR-UHFFFAOYSA-N 0.000 claims description 6
- WEJVZSAYICGDCK-UHFFFAOYSA-N Alexa Fluor 430 Chemical compound CC[NH+](CC)CC.CC1(C)C=C(CS([O-])(=O)=O)C2=CC=3C(C(F)(F)F)=CC(=O)OC=3C=C2N1CCCCCC(=O)ON1C(=O)CCC1=O WEJVZSAYICGDCK-UHFFFAOYSA-N 0.000 claims description 6
- WHVNXSBKJGAXKU-UHFFFAOYSA-N Alexa Fluor 532 Chemical compound [H+].[H+].CC1(C)C(C)NC(C(=C2OC3=C(C=4C(C(C(C)N=4)(C)C)=CC3=3)S([O-])(=O)=O)S([O-])(=O)=O)=C1C=C2C=3C(C=C1)=CC=C1C(=O)ON1C(=O)CCC1=O WHVNXSBKJGAXKU-UHFFFAOYSA-N 0.000 claims description 6
- ZAINTDRBUHCDPZ-UHFFFAOYSA-M Alexa Fluor 546 Chemical compound [H+].[Na+].CC1CC(C)(C)NC(C(=C2OC3=C(C4=NC(C)(C)CC(C)C4=CC3=3)S([O-])(=O)=O)S([O-])(=O)=O)=C1C=C2C=3C(C(=C(Cl)C=1Cl)C(O)=O)=C(Cl)C=1SCC(=O)NCCCCCC(=O)ON1C(=O)CCC1=O ZAINTDRBUHCDPZ-UHFFFAOYSA-M 0.000 claims description 6
- 238000005119 centrifugation Methods 0.000 claims description 6
- 238000000684 flow cytometry Methods 0.000 claims description 6
- 239000007788 liquid Substances 0.000 claims description 6
- 238000001819 mass spectrum Methods 0.000 claims description 6
- 230000010355 oscillation Effects 0.000 claims description 6
- 239000012192 staining solution Substances 0.000 claims description 6
- 238000004448 titration Methods 0.000 claims description 6
- 239000007853 buffer solution Substances 0.000 claims description 5
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 claims description 4
- 238000004043 dyeing Methods 0.000 claims description 4
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 claims description 4
- 238000002372 labelling Methods 0.000 claims description 4
- 210000004698 lymphocyte Anatomy 0.000 claims description 4
- 239000000243 solution Substances 0.000 claims description 4
- 238000012360 testing method Methods 0.000 claims description 4
- 239000012103 Alexa Fluor 488 Substances 0.000 claims description 3
- 239000012110 Alexa Fluor 594 Substances 0.000 claims description 3
- 239000012112 Alexa Fluor 633 Substances 0.000 claims description 3
- 239000012114 Alexa Fluor 647 Substances 0.000 claims description 3
- 239000012115 Alexa Fluor 660 Substances 0.000 claims description 3
- 239000012116 Alexa Fluor 680 Substances 0.000 claims description 3
- 239000012117 Alexa Fluor 700 Substances 0.000 claims description 3
- 239000012118 Alexa Fluor 750 Substances 0.000 claims description 3
- 238000010009 beating Methods 0.000 claims description 3
- 229960002685 biotin Drugs 0.000 claims description 3
- 235000020958 biotin Nutrition 0.000 claims description 3
- 239000011616 biotin Substances 0.000 claims description 3
- 238000007664 blowing Methods 0.000 claims description 3
- 239000008367 deionised water Substances 0.000 claims description 3
- 229910021641 deionized water Inorganic materials 0.000 claims description 3
- 239000000975 dye Substances 0.000 claims description 3
- 210000003743 erythrocyte Anatomy 0.000 claims description 3
- 210000000207 lymphocyte subset Anatomy 0.000 claims description 3
- 239000006166 lysate Substances 0.000 claims description 3
- 238000012083 mass cytometry Methods 0.000 claims description 3
- 210000005087 mononuclear cell Anatomy 0.000 claims description 3
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims description 3
- 238000010186 staining Methods 0.000 claims description 3
- JGVWCANSWKRBCS-UHFFFAOYSA-N tetramethylrhodamine thiocyanate Chemical compound [Cl-].C=12C=CC(N(C)C)=CC2=[O+]C2=CC(N(C)C)=CC=C2C=1C1=CC=C(SC#N)C=C1C(O)=O JGVWCANSWKRBCS-UHFFFAOYSA-N 0.000 claims description 3
- 238000003556 assay Methods 0.000 claims 1
- VYNDHICBIRRPFP-UHFFFAOYSA-N pacific blue Chemical compound FC1=C(O)C(F)=C2OC(=O)C(C(=O)O)=CC2=C1 VYNDHICBIRRPFP-UHFFFAOYSA-N 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 6
- 230000008859 change Effects 0.000 abstract description 4
- 238000011156 evaluation Methods 0.000 abstract description 3
- 238000004393 prognosis Methods 0.000 abstract description 3
- 239000000047 product Substances 0.000 description 34
- 210000001744 T-lymphocyte Anatomy 0.000 description 21
- 210000000822 natural killer cell Anatomy 0.000 description 17
- 239000011521 glass Substances 0.000 description 16
- 210000003719 b-lymphocyte Anatomy 0.000 description 14
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 5
- 230000036737 immune function Effects 0.000 description 4
- 210000000987 immune system Anatomy 0.000 description 4
- 230000002159 abnormal effect Effects 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 238000004949 mass spectrometry Methods 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 102100023990 60S ribosomal protein L17 Human genes 0.000 description 2
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- 102100037853 C-C chemokine receptor type 4 Human genes 0.000 description 2
- 101710149863 C-C chemokine receptor type 4 Proteins 0.000 description 2
- 102100036301 C-C chemokine receptor type 7 Human genes 0.000 description 2
- 102100025074 C-C chemokine receptor-like 2 Human genes 0.000 description 2
- 102100028990 C-X-C chemokine receptor type 3 Human genes 0.000 description 2
- 102100031658 C-X-C chemokine receptor type 5 Human genes 0.000 description 2
- 102100027207 CD27 antigen Human genes 0.000 description 2
- 102100032768 Complement receptor type 2 Human genes 0.000 description 2
- 102100021260 Galactosylgalactosylxylosylprotein 3-beta-glucuronosyltransferase 1 Human genes 0.000 description 2
- 102000006354 HLA-DR Antigens Human genes 0.000 description 2
- 108010058597 HLA-DR Antigens Proteins 0.000 description 2
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 description 2
- 101000716068 Homo sapiens C-C chemokine receptor type 6 Proteins 0.000 description 2
- 101000716065 Homo sapiens C-C chemokine receptor type 7 Proteins 0.000 description 2
- 101000916050 Homo sapiens C-X-C chemokine receptor type 3 Proteins 0.000 description 2
- 101000922405 Homo sapiens C-X-C chemokine receptor type 5 Proteins 0.000 description 2
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 description 2
- 101000941929 Homo sapiens Complement receptor type 2 Proteins 0.000 description 2
- 101000894906 Homo sapiens Galactosylgalactosylxylosylprotein 3-beta-glucuronosyltransferase 1 Proteins 0.000 description 2
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 2
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 2
- 101001043809 Homo sapiens Interleukin-7 receptor subunit alpha Proteins 0.000 description 2
- 101000884271 Homo sapiens Signal transducer CD24 Proteins 0.000 description 2
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 2
- 102100027268 Interferon-stimulated gene 20 kDa protein Human genes 0.000 description 2
- 102100021593 Interleukin-7 receptor subunit alpha Human genes 0.000 description 2
- 102100033627 Killer cell immunoglobulin-like receptor 3DL1 Human genes 0.000 description 2
- 101710089372 Programmed cell death protein 1 Proteins 0.000 description 2
- 102100038081 Signal transducer CD24 Human genes 0.000 description 2
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 230000001363 autoimmune Effects 0.000 description 2
- 230000005784 autoimmunity Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 239000007850 fluorescent dye Substances 0.000 description 2
- 210000002443 helper t lymphocyte Anatomy 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 230000001788 irregular Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 210000001616 monocyte Anatomy 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 101000945351 Homo sapiens Killer cell immunoglobulin-like receptor 3DL1 Proteins 0.000 description 1
- 101001109501 Homo sapiens NKG2-D type II integral membrane protein Proteins 0.000 description 1
- 101000971513 Homo sapiens Natural killer cells antigen CD94 Proteins 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- 108010043610 KIR Receptors Proteins 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 101000607575 Mus musculus Unknown protein from 2D-PAGE of fibroblasts Proteins 0.000 description 1
- 102100022680 NKG2-D type II integral membrane protein Human genes 0.000 description 1
- 102100021462 Natural killer cells antigen CD94 Human genes 0.000 description 1
- 101710160107 Outer membrane protein A Proteins 0.000 description 1
- 101000757777 Paralithodes camtschaticus Paralithocin 2 Proteins 0.000 description 1
- 101001113905 Rice tungro bacilliform virus (isolate Philippines) Protein P4 Proteins 0.000 description 1
- 101000871081 Toxoplasma gondii Dense granule protein 3 Proteins 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000001215 fluorescent labelling Methods 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000003284 homeostatic effect Effects 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 230000004727 humoral immunity Effects 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 238000010801 machine learning Methods 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 210000003519 mature b lymphocyte Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 210000000066 myeloid cell Anatomy 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/531—Production of immunochemical test materials
- G01N33/532—Production of labelled immunochemicals
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/531—Production of immunochemical test materials
- G01N33/532—Production of labelled immunochemicals
- G01N33/533—Production of labelled immunochemicals with fluorescent label
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
- G01N33/582—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
The invention discloses a detection kit for monitoring human immune state, which consists of CD3, CD4, CD8, CD16, CD19 and CD56 monoclonal antibodies. The antibodies are respectively provided with fluorescein suitable for flow type or metal elements suitable for mass flow type, and the immune state of a human body is evaluated by detecting main immune cell subgroups in human peripheral blood, so that the immune state and change of the human body are detected and monitored, and further, the tracking, prognosis and curative effect evaluation of clinical treatment are realized.
Description
Technical Field
The invention relates to the field of cytobiology and biomedical detection, in particular to a flow detection kit for monitoring human immune state, which is used for evaluating human immune state and predicting disease risk.
Background
Peripheral blood lymphocytes are classified into T lymphocytes, B lymphocytes, NK lymphocytes according to biological function and cell surface antigen expression. T lymphocytes are mainly involved in cellular immunity and express CD3 antigen; b cells are primarily involved in humoral immunity, expressing the CD19 antigen; NK cells express CD16 and/or CD56 and exert cytotoxic effects in the body spontaneously independent of antigen stimulation. Among these, T cells include helper T cells (Th) and suppressor T cells (Ts), which express CD4 and CD8, respectively.
Lymphocyte subpopulation analysis is an important indicator for detecting immune function, and generally reflects the current immune function, state and balance level of the organism. Moreover, the occurrence and development of various diseases are closely related to the state change of an immune system, the evaluation of the immune state is important for the disease risk of certain diseases, and the auxiliary diagnosis of certain diseases, such as autoimmune diseases, immunodeficiency diseases, malignant tumors, hematopathy, allergic diseases and the like, and has important significance in analyzing the pathogenesis, observing the curative effect and detecting the prognosis.
CN201811191483.2 discloses an autoimmune disease patient immune function assessment kit and an assessment method, the kit comprises: antihuman CD3, CD4, CD8, CD19, CD21, CD24, CD25, CD27, CD28, CD38, CD57, CD127, CD45RA, CXCR3, CXCR5, CCR4, CCR6, CCR7, HLA-DR, PD-1, IgD and IgM antibodies, all of which carry a fluorescein label.
CN201811191491.7 discloses a kit and a method for comprehensively evaluating human peripheral blood immune cell functions, wherein the kit comprises anti-human CD3, CD4, CD8, CD19, CD21, CD24, CD25, CD27, CD28, CD38, CD56, CD57, CD94, CD127, CD45RA, CXCR3, CXCR5, CCR4, CCR6, CCR7, HLA-DR, PD-1, P30, P46, NKG2D, KIR (NKB1), gamma delta, V delta 2, IgD and IgM antibodies, and all the antibodies carry fluorescein labels.
Disclosure of Invention
The technical problem to be solved by the invention is a kit for monitoring the human immune state, which is used for detecting the proportion of T lymphocytes, B lymphocytes and NK cells in peripheral blood and evaluating the human immune state. Therefore, the invention provides a kit for detecting the composition of peripheral blood lymphocytes and evaluating the immune state of a human body.
The kit consists of CD3, CD4, CD8, CD16, CD19 and CD56 monoclonal antibodies, and is not limited to antibody clone numbers; the method is not limited to the color of the fluorescent label of the antibody, the mass number of the metal label, or other methods for labeling and detecting the antibody.
The detection instrument used by the detection kit is not limited to a fluorescence flow cytometer and a mass spectrometer.
The technical problem solved by the invention can be further realized by adopting the following measures.
A kit, wherein the reagent consists of monoclonal antibodies of CD3, CD4, CD8, CD16, CD19 and CD 56;
the CD3, CD4, CD8, CD16, CD19 and CD56 monoclonal antibodies respectively carry six fluorescein suitable for flow cytometry or six metal elements suitable for mass spectrum flow; the six fluorescein or metal elements are different from each other.
Preferably, the aforementioned kit comprises fluorescein selected from Biotin, FITC, PE, TRITC, APC, Alexa Fluor 405, Alexa Fluor 430, Alexa Fluor 488, Alexa Fluor 532, Alexa Fluor 546, Alexa Fluor 594, Alexa Fluor 633, Alexa Fluor 647, Alexa Fluor 660, Alexa Fluor 680, Alexa Fluor 700, Alexa Fluor750, APC/Cy7, APC/efour 750, APC/FireTM750, PerCP/Cy5.5, PerCP-eFlour 710, PE/Cy7, PE/Cy5, PE/Dazle, PE-CF, Pacific 594, Brilliant Violli 421, Brillii Villii 421, Brilliant 78600, Brilliant Violet 702, Bright Fluoret 436, Bright Fluoret 750, Bright Fluor Bright Fluoret 750, Bright prof 750, Bright Fluor Bright prof 450, Bright prof 750, Bright Fluor Bright6, Bright Fluor, Any one of eFluor 710, eFluor 780, BD Horizon BB515, BD Horizon PE-CF594, BD Horizon BV421, BD Horizon BV480, BD Horizon BV510, BD Horizon BV605, BD Horizon BV650, BD Horizon BV711, BD Horizon BV786, BD Horizon BUV395, BD Horizon BUV496, BD Horizon BUV737, BD Horizon BUV805, BD Horizon APC R700, Cy3, Cy5, Cy 7.
Preferably, the metal element In the kit is any one selected from 89Y, 106Cd, 110Cd, 111Cd, 112Cd, 113Cd, 114Cd, 115In, 116Cd, 139La, 141Pr, 142Nd, 143Nd, 144Nd, 145Nd, 146Nd, 147Sm, 148Nd, 149Sm, 150Nd, 151Eu, 152Sm, 153Eu, 154Sm, 155Gd, 156Gd, 157Gd, 158Gd, 159Tb, 160Gd, 161Dy, 162Dy, 163Dy, 164Dy, 165Ho, Er, 167Er, 168Er, 169Tm, 170Er, 171Yb, 172Yb, 173Yb, 174Yb, 175Lu, 176Yb, 197Au, 198Pt and 209 Bi.
Preferably, the labeled antibody of the kit comprises the following components: the fluorescent or metal-labeled CD3, CD4, CD8, CD16, CD19 and CD56 account for 0.5-97.5% of the total volume percentage;
the technical problem to be solved by the invention is solved by the following technical scheme. The preparation method of the kit provided by the invention comprises the following steps: 1) carrying out fluorescence labeling or metal labeling on the antibody; 2) determining the amount of antibody used by titration; 3) and (3) putting the metered marked antibody into a reagent bottle, uniformly mixing, sealing, and keeping the fluorescent antibody away from light.
The technical problem solved by the invention is realized by adopting the following technical scheme. The invention provides application of a kit in detecting the immune state of a human body.
Preferably, the use of the aforementioned kit for detecting the immune status of a human, said kit being used for detecting the proportion of immune cells in peripheral blood;
the proportion of immune cells in the peripheral blood is distinguished by the unique immunophenotypic characteristics of the surface of each type of immune cell.
Preferably, the kit is used for detecting the immune state of a human body, wherein the detection sample is from the peripheral blood of the human body, and the human body comprises physical testers of all age groups.
Preferably, the kit is used for detecting the immune age of a human body, wherein the kit is used for detecting the ratio of T lymphocytes, B lymphocytes and NK cells in human peripheral blood mononuclear cells.
Preferably, the kit is used for detecting the immune age of a human body, wherein the detection comprises the following steps: 1) isolating peripheral blood mononuclear cells; 2) detecting the number and proportion of lymphocyte subpopulations in the peripheral blood of the sample by a flow cytometer or a mass spectrometer; 3) and determining the immune state of the detection sample according to the quantity and the proportion of the immune cell subsets in the peripheral blood.
Preferably, the kit is used for monitoring the immune state of a human body, and the flow detection preparation of the detection sample comprises the following steps:
1) collecting not less than 100 mu L of human peripheral blood as a detection sample; immediately detecting the sample after collection, or refrigerating at 2-8 ℃ and detecting within 48 h;
2) respectively sucking 0.5-20 mu L of 6 reagents from the kit into a flow tube, adding the detection sample into the flow tube, and uniformly mixing the reagents by oscillation to obtain a first pre-sample;
3) incubating the first pre-sample at normal temperature in a dark place for 10-20 min, preferably 15min, or at 2-8 ℃ for 20-40 min, preferably 30min to obtain a second pre-sample;
4) adding 300 mu L-2 mL of erythrocyte lysate into the second pre-sample, oscillating and uniformly mixing, and incubating for 2min at normal temperature in a dark place to obtain a third pre-sample;
5) centrifuging the third pre-sample to obtain a fourth pre-sample; the centrifugation condition of the centrifugation is 500 Xg, normal temperature and 5 min;
6) discarding the supernatant of the fourth pre-sample, and adding PBS buffer solution into the residual sample after discarding the supernatant to carry out resuspension to obtain a detection sample;
7) and (4) detecting the detection sample on a flow cytometer.
The mass spectrometric detection preparation of the detection sample comprises the following steps:
1) collecting not less than 5mL of peripheral blood of a human body as a detection sample; immediately detecting the sample after collection, or refrigerating at 2-8 ℃ and detecting within 48 h;
2) separating a detection sample by using lymphocyte separating medium to obtain mononuclear cells;
3) counting the cells, taking 1X 106~3×106A cell;
4) using PBS buffer solution to prepare 194Pt (1mM) dead and live staining solution with final concentration of 0.25 mu M, taking 50-1.5 mL of 194Pt dead and live staining solution to resuspend cells, preferably 100 mu L, and staining on ice for 5 min;
5) adding FACS Buffer of 100-1.5 mL, preferably 500 μ L, into each sample, resuspending cells, centrifuging at 2-8 ℃ for 400g/5min, and discarding the supernatant;
6) adding 20-1.5 mL of confining liquid, preferably 50 μ L, into each sample, resuspending the cells, and confining on ice for 20 min-1 h, preferably 20 min;
7) respectively sucking 0.5-20 mu L of 6 metal antibodies from the kit into a centrifugal tube, and adjusting the total volume to 50 mu L by using confining liquid;
8) adding the detection sample into the centrifuge tube, wherein the total volume is 100 mu L, and uniformly mixing the detection sample and the centrifuge tube by oscillation;
9) gently blowing and beating the uniformly mixed cells, and dyeing on ice for 20-60 min, preferably 30 min;
10) adding 1mL of FACS Buffer into each sample, resuspending cells, centrifuging at 2-8 ℃ for 400g/5min, and discarding the supernatant;
11) preparing Ir dye solution with final concentration of 100-500 nM, preferably 250nM, by using Fix and Perm Buffer, taking 200 mu L-1.5 mL of resuspended cells from each sample, and incubating for 1h at room temperature;
12) discarding the supernatant, using 500 mu L-1.5 mL FACS Buffer, preferably 1mL, resuspending the cells, centrifuging at 2-8 ℃ for 800g/5min, discarding the supernatant, resuspending the cells with deionized water, and detecting the detection sample on a mass cytometry.
Through the technical route, the kit for monitoring the immune state of the human body and the application thereof provided by the invention have at least the following advantages:
with the change of modern human life style, many people are in a sub-health state, the kit detects the composition and proportion of peripheral blood lymphocytes, establishes an organism immune state scoring system, evaluates the autoimmunity, assists in diagnosing certain diseases, analyzes the pathogenesis, observes the curative effect and detects the prognosis;
the detection can find whether the physical examiner has the problem of abnormal immune state: for people with abnormal immune state, the immunity is mediated by adjusting the self state or adopting a medical means to intervene and enhance the immunity under the guidance of doctors.
The kit provided by the invention provides a group of six-color antibody combination schemes by utilizing six antibodies, single-tube detection of a single sample is realized by applying the kit provided by the invention on a multi-color flow cytometer or mass spectrum flow cytometer platform, quantitative analysis can be carried out on T lymphocytes, B lymphocytes and NK cells through manual circle gate, and the immunocompetence of a physical examinee can be effectively monitored.
The beneficial effects produced by adopting the invention are as follows:
1) by adopting the kit, peripheral blood is collected through veins, and T lymphocytes, B lymphocytes and NK cells of the peripheral blood can be rapidly and accurately quantitatively analyzed;
2) the kit is suitable for monitoring the immune state of physical testers in all age groups;
3) the kit has strong specificity and high sensitivity; each antibody can be accurately measured only by 0.5 mu L, and the repeatability reproducibility of the measured data is good;
4) the sample is easy to obtain, the report period is short, and the detection time and the cost are effectively reduced.
The above description only outlines the technical scheme of the present invention, and the specific implementation can be implemented according to the content of the kit specification, and the following detailed description is given with reference to the preferred embodiment of the present invention.
Drawings
FIG. 1 shows the mass spectrometric validity test results of 6 antibodies in the kit of the present invention.
Detailed Description
To further illustrate the technical means and practical effects of the present invention for achieving the predetermined objects, the following embodiments are provided to describe the structure, features, specific embodiments and effects of the kit for monitoring human immune status and its applications according to the present invention in detail. In the following description, different "one embodiment" or "an embodiment" refers to not necessarily the same embodiment. Furthermore, the particular features, structures, or characteristics may be combined in any suitable manner in one or more embodiments.
The kit for monitoring the immune state of the human body, provided by the invention, is suitable for physical examination persons of all ages.
And analyzing the proportion of T cells, B cells and NK cells in peripheral blood by using a flow cytometer or a mass spectrometer to evaluate the immune state.
According to the invention, through analyzing the unique markers of the T lymphocytes, the B lymphocytes and the NK cells, a monitoring scheme based on CD3, CD4, CD8, CD16, CD19, CD56 and the like is established, the mass spectrum flow detection is utilized to detect the basic samples of hundreds of healthy people, an immune state model suitable for Chinese people and reflecting the steady state of peripheral blood lymphocytes is established, the correlation between the proportion of the individual peripheral blood lymphocytes and the immune state can be accurately evaluated, and therefore, whether the immunity is abnormal or disordered or not is judged, and the individual is helped to carry out correct health management.
CD3 is expressed on T lymphocytes, thymocytes, and NK cells.
CD4 is expressed in helper T lymphocyte, peripheral blood monocyte, macrophage and dendritic cell, and is mainly used for diagnosis of T lymphocyte leukemia and lymphoma and immune function detection.
CD8 is expressed on killer or suppressor T lymphocytes, thymocytes, and certain NK cells.
CD16 was expressed on normal granulocytes, NK cell nuclei large granular T cells.
CD19 is expressed on B cells late nuclear mature B cells.
CD56 is expressed on NK cells, partial T cells and monocytes, and a few proliferating myeloid cells may also be weakly expressed.
The fluorescein-or metal element-labeled monoclonal antibodies CD3, CD4, CD8, CD16, CD19 and CD56 used in the examples of the present invention are commercially available under the american Biolegend brand, but the composition of the kit of the present invention is not limited to the raw materials of the brands involved in the examples.
Fluorescein used in the examples of the invention is commercially available under the brand name ThermoFisher;
the metal elements and the marking kit thereof used in the embodiment of the invention are commercially available under the American fluent brand;
on the basis of the previous research, the immune state is monitored, a corresponding flow cytometry or mass spectrum flow cytometry scheme is established, and the immune age of a human body is measured by combining six antibodies of CD3, CD4, CD8, CD16, CD19 and CD56 which are labeled by fluorescence.
The monitoring method is suitable for physical examination persons of all ages.
The optimal dosage of the antibody is determined by methods such as antibody titration, the dosage of a single antibody is within the range of 0.1-4 mu L, ideal grouping can be achieved, and the detection effect can reach the expectation.
The sample obtained when the immune state monitoring model is established is taken from peripheral blood of a healthy person.
200 healthy human samples are selected to be detected by peripheral blood T lymphocytes, B lymphocytes and NK cells.
First, the ratio of T lymphocytes, B lymphocytes and NK cells in peripheral blood of a healthy human sample is measured. The method comprises the following steps:
the kit is adopted, and consists of CD3, CD4, CD8, CD16, CD19 and CD56 monoclonal antibodies, is not limited to antibody clone numbers, and is respectively marked with six fluorescein suitable for flow cytometry detection or six metals suitable for mass spectrometry flow cytometry detection;
preferably, the aforementioned kit comprises fluorescein selected from Biotin, FITC, PE, TRITC, APC, Alexa Fluor 405, Alexa Fluor 430, Alexa Fluor 488, Alexa Fluor 532, Alexa Fluor 546, Alexa Fluor 594, Alexa Fluor 633, Alexa Fluor 647, Alexa Fluor 660, Alexa Fluor 680, Alexa Fluor 700, Alexa Fluor750, APC/Cy7, APC/efour 750, APC/FireTM750, PerCP/Cy5.5, PerCP-eFlour 710, PE/Cy7, PE/Cy5, PE/Dazle, PE-CF, Pacific 594, Brilliant Violli 421, Brillii Villii 421, Brilliant 78600, Brilliant Fluoret 436, Bright Fluoret 750, Bright Fluor Fluoret 750, Bright Fluor Bright 750, Bright Fluoret 750, Bright Fluor Bright fluoride 750, Bright Fluor Bright fluoride 750, Bright Fluor, Any one of eFluor 780, BD Horizon BB515, BD Horizon PE-CF594, BD Horizon BV421, BD Horizon BV480, BD Horizon BV510, BD Horizon BV605, BD Horizon BV650, BD Horizon BV711, BD Horizon BV786, BD Horizon BUV395, BD Horizon BUV496, BD Horizon BUV737, BD Horizon BUV805, BD Horizon APC R700, Cy3, Cy5, Cy 7.
Preferably, the metal element In the kit is any one selected from 89Y, 106Cd, 110Cd, 111Cd, 112Cd, 113Cd, 114Cd, 115In, 116Cd, 139La, 141Pr, 142Nd, 143Nd, 144Nd, 145Nd, 146Nd, 147Sm, 148Nd, 149Sm, 150Nd, 151Eu, 152Sm, 153Eu, 154Sm, 155Gd, 156Gd, 157Gd, 158Gd, 159Tb, 160Gd, 161Dy, 162Dy, 163Dy, 164Dy, 165Ho, Er, 167Er, 168Er, 169Tm, 170Er, 171Yb, 172Yb, 173Yb, 174Yb, 175Lu, 176Yb, 197Au, 198Pt and 209 Bi.
Preferably, the fluorescein in the kit is selected from any one of FITC, PE, APC, PerCP/Cy5.5, APC/Cy7 and PE/Cy 7.
Preferably, the fluorescence labeled antibody of the kit is CD3-FITC, CD4-PerCP/Cy5.5, CD8-APC/Cy7, CD16-PE, CD19-PE/Cy7 and CD56-APC respectively.
Preferably, the metal element In the kit is selected from any one of 115In, 197Au, 198Pt, 175Lu, 148Nd and 141 Pr.
Preferably, the metal labeled antibodies of the kit are 115In-CD3, 197Au-CD4, 198Pt-CD8, 175Lu-CD16, 148Nd-CD19 and 141Pr-CD56 respectively.
Preferably, the labeled antibody of the kit comprises the following components: the fluorescent or metal-labeled CD3, CD4, CD8, CD16, CD19 and CD56 account for 0.5-97.5 percent of the total volume percentage.
The preparation method of the kit comprises the following steps:
1) carrying out fluorescence or metal labeling on the antibody;
2) performing antibody titration;
3) and (4) subpackaging the labeled antibody according to the titration result.
The storage conditions of the kit are as follows: and (3) storing the fluorescent antibody kit in a dark place at the temperature of 2-8 ℃.
After the preparation of the kit is completed, the human peripheral blood from the 200 samples is detected.
Preferably, the kit is used for monitoring the immune state of a human body, and the flow detection preparation of the detection sample comprises the following steps:
1) collecting not less than 100 mu L of human peripheral blood as a detection sample; immediately detecting the sample after collection, or refrigerating at 2-8 ℃ and detecting within 48 h;
2) respectively sucking 0.5-20 mu L of 6 reagents from the kit into a flow tube, adding the detection sample into the flow tube, and uniformly mixing the reagents by oscillation to obtain a first pre-sample;
3) incubating the first pre-sample at normal temperature in a dark place for 10-20 min, preferably 15min, or at 2-8 ℃ for 20-40 min, preferably 30min to obtain a second pre-sample;
4) adding 300 mu L-2 mL of erythrocyte lysate into the second pre-sample, oscillating and uniformly mixing, and incubating for 2min at normal temperature in a dark place to obtain a third pre-sample;
5) centrifuging the third pre-sample to obtain a fourth pre-sample; the centrifugation condition of the centrifugation is 500 Xg, normal temperature and 5 min;
6) discarding the supernatant of the fourth pre-sample, adding PBS buffer (pH7.4) into the residual sample after discarding the supernatant, and resuspending to obtain a detection sample;
7) and (4) detecting the detection sample on a flow cytometer.
The mass spectrometric detection preparation of the detection sample comprises the following steps:
1) collecting not less than 5mL of peripheral blood of a human body as a detection sample; immediately detecting the sample after collection, or refrigerating at 2-8 ℃ and detecting within 48 h;
2) separating a detection sample by using lymphocyte separating medium to obtain mononuclear cells;
3) counting the cells, taking 1X 106~3×106A cell;
4) using PBS buffer solution (pH7.4) to prepare 194Pt (1mM) dead and live staining solution with final concentration of 0.25. mu.M, taking 50. mu.L-1.5 mL of 194Pt dead and live staining solution to resuspend cells, preferably 100. mu.L, and staining on ice for 5 min;
5) adding FACS Buffer of 100-1.5 mL, preferably 500 μ L, into each sample, resuspending cells, centrifuging at 2-8 ℃ for 400g/5min, and discarding the supernatant;
6) adding 20-1.5 mL of confining liquid, preferably 50 μ L, into each sample, resuspending the cells, and confining on ice for 20 min-1 h, preferably 20 min;
7) respectively sucking 0.5-20 mu L of 6 metal antibodies from the kit into a centrifugal tube, and adjusting the total volume to 50 mu L by using confining liquid;
8) adding the detection sample into the centrifuge tube, wherein the total volume is 100 mu L, and uniformly mixing the detection sample and the centrifuge tube by oscillation;
9) gently blowing and beating the uniformly mixed cells, and dyeing on ice for 20-60 min, preferably 30 min;
10) adding 1mL of FACS Buffer into each sample, resuspending cells, centrifuging at 2-8 ℃ for 400g/5min, and discarding the supernatant;
11) preparing Ir dye solution with final concentration of 100-500 nM, preferably 250nM, by using Fix and Perm Buffer, taking 200 mu L-1.5 mL of resuspended cells from each sample, and incubating for 1h at room temperature;
12) discarding the supernatant, using 500 mu L-1.5 mL FACS Buffer, preferably 1mL, resuspending the cells, centrifuging at 2-8 ℃ for 800g/5min, discarding the supernatant, resuspending the cells with deionized water, and detecting the detection sample on a mass cytometry.
The application of the kit is based on a flow cytometer or a mass spectrometer, and the kit is used for detecting the proportion of T lymphocytes, B lymphocytes and NK cells in human peripheral blood.
From the results of the measurement of the ratios of T lymphocytes, B lymphocytes and NK cells in the peripheral blood of the 200 samples, a reference range was established, and this range was considered as an immune homeostasis.
The invention also provides application of the kit in monitoring the immune state of a human body.
Preferably, the kit is used for monitoring the immune state of a human body, and when the kit is used for physical examination of the immune state, the detection comprises the following steps:
1) detecting the proportion of T lymphocytes, B lymphocytes and NK cells of the detection sample by a flow cytometer or a mass spectrometer;
2) the immune status of the monitored sample is assessed against the homeostatic model described above according to the ratio of T lymphocytes, B lymphocytes and NK cells.
Example 1
Preparation of a reagent:
and 12.5 mu L of each monoclonal antibody of CD3-FITC, CD4-PerCP/Cy5.5, CD8-APC/Cy7, CD16-PE, CD19-PE/Cy7 and CD56-APC is respectively added into a plastic tube or a glass reagent bottle and uniformly mixed, and the fluorescent antibody needs to be stored in a dark place to obtain 100 parts of the product, wherein the using amount of the product corresponding to each part is 0.75 mu L.
Example 2
Preparation of a reagent:
the method comprises the following steps of respectively taking 25 mu L of CD3-FITC, CD4-PerCP/Cy5.5, CD8-APC/Cy7, CD16-PE, CD19-PE/Cy7 and CD56-APC monoclonal antibodies, adding the antibodies into a plastic tube or a glass reagent bottle, uniformly mixing, and storing the fluorescent antibodies in a dark place to obtain 100 parts of the product, wherein the using amount of the product corresponding to each part is 1.5 mu L.
Example 3
Preparation of a reagent:
the method comprises the following steps of respectively taking 50 mu L of CD3-FITC, CD4-PerCP/Cy5.5, CD8-APC/Cy7, CD16-PE, CD19-PE/Cy7 and CD56-APC monoclonal antibodies, adding the antibodies into a plastic tube or a glass reagent bottle, uniformly mixing, and storing the fluorescent antibodies in a dark place to obtain 100 parts of the product, wherein the using amount of each part of the product is 3 mu L.
Example 4
Preparation of a reagent:
the method comprises the following steps of respectively taking 100 mu L of CD3-FITC, CD4-PerCP/Cy5.5, CD8-APC/Cy7, CD16-PE, CD19-PE/Cy7 and CD56-APC monoclonal antibodies, adding the antibodies into a plastic tube or a glass reagent bottle, uniformly mixing, and storing the fluorescent antibodies in a dark place to obtain 100 parts of the product, wherein the using amount of each part of the product is 6 mu L.
Example 5
Preparation of a reagent:
the method comprises the following steps of respectively taking 200 mu L of CD3-FITC, CD4-PerCP/Cy5.5, CD8-APC/Cy7, CD16-PE, CD19-PE/Cy7 and CD56-APC monoclonal antibodies, adding the antibodies into a plastic tube or a glass reagent bottle, uniformly mixing, and storing the fluorescent antibodies in a dark place to obtain 100 parts of the product, wherein the using amount of the product corresponding to each part is 12 mu L.
Example 6
Preparation of a reagent:
the method comprises the following steps of respectively taking 400 mu L of CD3-FITC, CD4-PerCP/Cy5.5, CD8-APC/Cy7, CD16-PE, CD19-PE/Cy7 and CD56-APC monoclonal antibodies, adding the antibodies into a plastic tube or a glass reagent bottle, uniformly mixing, and storing the fluorescent antibodies in a dark place to obtain 100 parts of the product, wherein the using amount of each part of the product is 24 mu L.
Example 7
Preparation of a reagent:
CD3-FITC, CD4-PerCP/Cy5.5, CD8-APC/Cy7, CD16-PE, CD19-PE/Cy7 and CD56-APC six monoclonal antibodies, wherein one of the antibodies (any one of the antibodies) is 12.5 mu L, the rest of each antibody is 400 mu L respectively, the antibodies are added into a plastic tube or a glass reagent bottle and mixed uniformly, the fluorescent antibodies are stored in a dark place, and then 100 parts of the product of the invention is obtained, and the using amount of each part of the product is 20.125 mu L.
Example 8
Preparation of a reagent:
CD3-FITC, CD4-PerCP/Cy5.5, CD8-APC/Cy7, CD16-PE, CD19-PE/Cy7 and CD56-APC six monoclonal antibodies, wherein 25 mu L of one antibody (any one antibody) and 400 mu L of the rest antibodies are respectively taken and added into a plastic tube or a glass reagent bottle to be uniformly mixed, and the fluorescent antibodies need to be kept away from light to be stored, so that 100 parts of the product of the invention is prepared, and the using amount of the corresponding product of each part is 20.25 mu L.
Example 9
Preparation of a reagent:
CD3-FITC, CD4-PerCP/Cy5.5, CD8-APC/Cy7, CD16-PE, CD19-PE/Cy7 and CD56-APC six monoclonal antibodies, wherein 50 mu L of one antibody (any one antibody) and 400 mu L of the rest antibodies are respectively added into a plastic tube or a glass reagent bottle and mixed uniformly, and the fluorescent antibodies are stored in a dark place to obtain 100 parts of the product, and the using amount of the product corresponding to each part is 20.50 mu L.
Example 10
Preparation of a reagent:
the method comprises the following steps of preparing 100 mu L of CD3-FITC, CD4-PerCP/Cy5.5, CD8-APC/Cy7, CD16-PE, CD19-PE/Cy7 and CD56-APC six monoclonal antibodies, wherein one (any one) of the antibodies is prepared, 400 mu L of the rest antibodies is prepared respectively, adding the antibodies into a plastic tube or a glass reagent bottle, uniformly mixing, and storing the fluorescent antibodies in a dark place to obtain 100 parts of the product, wherein the using amount of the product corresponding to each part is 21 mu L.
Example 11
Preparation of a reagent:
CD3-FITC, CD4-PerCP/Cy5.5, CD8-APC/Cy7, CD16-PE, CD19-PE/Cy7 and CD56-APC six monoclonal antibodies, wherein 200 mu L of one antibody (any one antibody) and 400 mu L of the rest antibodies are respectively taken and added into a plastic tube or a glass reagent bottle to be uniformly mixed, and the fluorescent antibodies need to be kept away from light to be stored, so that 100 parts of the product of the invention is prepared, and the using amount of the corresponding product of each part is 22 mu L.
Example 12
Preparation of a reagent:
CD3-FITC, CD4-PerCP/Cy5.5, CD8-APC/Cy7, CD16-PE, CD19-PE/Cy7 and CD56-APC six monoclonal antibodies, wherein 400 mu L of one antibody (any one antibody) and 12.5 mu L of the rest antibodies are respectively added into a plastic tube or a glass reagent bottle and mixed uniformly, and the fluorescent antibodies are stored in a dark place to obtain 100 parts of the product, wherein the using amount of each part of the product is 4.625 mu L.
Example 13
Preparation of a reagent:
CD3-FITC, CD4-PerCP/Cy5.5, CD8-APC/Cy7, CD16-PE, CD19-PE/Cy7, CD56-APC six monoclonal antibodies, wherein 400 mu L of one antibody (any one antibody) and 25 mu L of the rest antibodies are respectively taken and added into a plastic tube or a glass reagent bottle to be uniformly mixed, and the fluorescent antibodies need to be kept away from light to be stored, so that 100 parts of the product of the invention is prepared, and the using amount of the corresponding product of each part is 5.25 mu L.
Example 14
Preparation of a reagent:
CD3-FITC, CD4-PerCP/Cy5.5, CD8-APC/Cy7, CD16-PE, CD19-PE/Cy7 and CD56-APC six monoclonal antibodies, wherein 400 mu L of one antibody (any one antibody) and 50 mu L of the rest antibodies are respectively added into a plastic tube or a glass reagent bottle and mixed uniformly, and the fluorescent antibodies are stored in a dark place to obtain 100 parts of the product, and the using amount of the product corresponding to each part is 6.25 mu L.
Example 15
Preparation of a reagent:
CD3-FITC, CD4-PerCP/Cy5.5, CD8-APC/Cy7, CD16-PE, CD19-PE/Cy7 and CD56-APC six monoclonal antibodies, wherein 400 mu L of one antibody (any one antibody) and 100 mu L of the rest antibodies are respectively taken and added into a plastic tube or a glass reagent bottle to be uniformly mixed, and the fluorescent antibodies need to be kept away from light to be stored, so that 100 parts of the product of the invention is prepared, and the using amount of the corresponding product of each part is 9 mu L.
Example 16
Preparation of a reagent:
CD3-FITC, CD4-PerCP/Cy5.5, CD8-APC/Cy7, CD16-PE, CD19-PE/Cy7 and CD56-APC six monoclonal antibodies, wherein 400 mu L of one antibody (any one antibody) and 200 mu L of the other antibodies are respectively taken and added into a plastic tube or a glass reagent bottle to be uniformly mixed, and the fluorescent antibodies need to be kept away from light to be stored, so that 100 parts of the product of the invention is prepared, and the using amount of the corresponding product of each part is 14 mu L.
Example 17
Preparation of a reagent:
mass spectrum flow type antibodies 115In-CD3, 197Au-CD4, 198Pt-CD8, 175Lu-CD16, 148Nd-CD19 and 141Pr-CD56 are respectively subpackaged In different tubes according to the proportion of examples 1-16, the antibodies are not mixed, each antibody is independently subpackaged into one tube, 6 tubes of antibodies are contained In one kit, namely 100 human parts of the product are obtained, and six antibodies are mixed In proportion before dyeing and are ready for use.
After the kit is prepared, the usage amount of the product is marked on the kit.
Multiple monitoring of the same test sample using the kit of the same embodiment produces reproducible results.
The mass spectrometry validity detection results of 6 antibodies in the kit are shown in figure 1.
Through experiments, a sample of the subject is detected by using the mass spectrometry flow antibody kit of the above embodiment. B001-B010 represent different subject numbers, and Table 1 shows that the abundance of various protein markers in immune cells is different among different individuals.
Table 1 example of positive ratios of 6 markers for flow detection samples using the kit of example 4
B001 | B002 | B003 | B004 | B005 | B006 | B007 | B008 | B009 | B010 | |
CD3 | 0.607 | 0.593 | 0.377 | 0.554 | 0.391 | 0.585 | 0.695 | 0.567 | 0.754 | 0.557 |
CD4 | 0.482 | 0.444 | 0.238 | 0.250 | 0.257 | 0.376 | 0.363 | 0.356 | 0.477 | 0.443 |
CD8 | 0.212 | 0.117 | 0.131 | 0.298 | 0.148 | 0.192 | 0.231 | 0.185 | 0.219 | 0.052 |
CD16 | 0.118 | 0.202 | 0.208 | 0.2 | 0.167 | 0.19 | 0.183 | 0.117 | 0.08 | 0.114 |
CD19 | 0.108 | 0.130 | 0.193 | 0.050 | 0.215 | 0.119 | 0.099 | 0.133 | 0.100 | 0.103 |
CD56 | 0.098 | 0.157 | 0.162 | 0.119 | 0.099 | 0.173 | 0.088 | 0.192 | 0.104 | 0.124 |
The kit for detecting the human immune state provided by the invention utilizes the expression abundance of corresponding proteins detected by 6 antibodies of a subject to perform dimensionality reduction analysis and machine learning calculation, and establishes an immune state scoring system for detection and evaluation of various groups of people.
The kit for monitoring the immune state provided by the invention is used for monitoring a physical examination sample and comparing the physical conditions of a physical examinee. As shown in table 2, when the immune status score is less than 0.5, it indicates that the subjects have good autoimmune status, good aging degree of immune system, and low immune injury degree, and is matched with the subjects having no bad life habits and good physical conditions; when the immune state score is more than 0.5, the autoimmune state of the subject is lower than the normal level, the aging degree of the immune system is high, the immune injury degree is high, and the immune system corresponds to the physical conditions of 'disordered work and rest, irregular diet and easy fatigue'.
TABLE 2 examination table of immune status and general physical condition of physical examination person
Detecting the number of samples | Immune status score | Physical condition of the subject |
87 examples of | <0.5 | Has no bad living habits and good physical condition |
113 example (b) | >0.5 | Disordered daily work and rest, irregular diet and easy fatigue |
The kit can be used for rapidly and accurately detecting and evaluating the autoimmunity.
The above description is only a preferred embodiment of the present invention, and is not intended to limit the present invention in any way, and any simple modification, equivalent change and modification made to the above embodiment according to the technical spirit of the present invention are still within the scope of the technical solution of the present invention.
Claims (10)
1. A kit, characterized in that:
the reagent in the kit consists of monoclonal antibodies of CD3, CD4, CD8, CD16, CD19 and CD 56;
the CD3, CD4, CD8, CD16, CD19 and CD56 monoclonal antibodies respectively carry six fluorescein suitable for flow cytometry or six metal elements suitable for mass spectrum flow; the six fluorescein or metal elements are different from each other.
2. The kit according to claim 1,
the fluorescein is selected from the group consisting of Biotin, FITC, PE, TRITC, APC, Alexa Fluor 405, Alexa Fluor 430, Alexa Fluor 488, Alexa Fluor 532, Alexa Fluor 546, Alexa Fluor 594, Alexa Fluor 633, Alexa Fluor 647, Alexa Fluor 660, Alexa Fluor 680, Alexa Fluor 700, Alexa Fluor750, APC/Cy7, APC/eflor 750, APC/FireTM750, PerCP/Cy5.5, PerCP-eFlour 710, PE/7, PE/5, PE/Dazzle 594, PE-CF, Pacific Blue, 780, Brilliant Violet 421, Brilliant villi Villi 510, Brilliant Ville 605, Brilliant Ville 510, Brilliant Fluor 650, Brilliant Fluor 710, Bright Fluor750, Bright Fluor750, APC/Cy Fluor Cy 35, Bright Fluor Villiant 750, Bright Fluor750, Bright fluoride 750, Bright 410, Bright Fluor Villier 750, Bright fluoride 750, Bright Fluor Brilliant 750, Bri, Any six of BD Horizon BB515, BD Horizon PE-CF594, BD Horizon BV421, BD Horizon BV480, BD Horizon BV510, BD Horizon BV605, BD Horizon BV650, BD Horizon BV711, BD Horizon BV786, BD Horizon BUV395, BD Horizon BUV496, BD Horizon BUV737, BD Horizon BUV805, BD Horizon APC R700, Cy3, Cy5, Cy 7;
the metal elements are selected from any six of 89Y, 106Cd, 110Cd, 111Cd, 112Cd, 113Cd, 114Cd, 115In, 116Cd, 139La, 141Pr, 142Nd, 143Nd, 144Nd, 145Nd, 146Nd, 147Sm, 148Nd, 149Sm, 150Nd, 151Eu, 152Sm, 153Eu, 154Sm, 155Gd, 156Gd, 157Gd, 158Gd, 159Tb, 160Gd, 161Dy, 162Dy, 163Dy, 164Dy, 165Ho, 166Er, 167Er, 168Er, 169Tm, 170Er, 171Yb, 172Yb, 173Yb, 174Yb, 175Lu, 176Yb, 197Au, 198Pt and 209 Bi.
3. The kit according to claim 1,
the reagent in the kit comprises the following components:
the fluorescent or metal-labeled CD3, CD4, CD8, CD16, CD19 and CD56 account for 0.5-97.5 percent of the total volume percentage.
4. A method for preparing the kit according to any one of claims 1 to 3, characterized in that it comprises the following steps:
1) carrying out fluorescence or metal labeling on the antibody;
2) performing antibody titration;
3) and (4) subpackaging the labeled antibody according to the titration result.
5. Use of a kit according to any one of claims 1 to 3 for monitoring the immune status of a human.
6. Use of a kit according to claim 5 for monitoring the immune status of a human, characterized in that the kit is used for detecting the proportion of immune cells in peripheral blood;
the proportion of immune cells in the peripheral blood is distinguished by the unique immunophenotypic characteristics of the surface of each type of immune cell.
7. Use of a kit according to claim 5 for monitoring the immune status of a human, wherein the sample to be monitored is derived from the peripheral blood of the human.
8. Use of a kit according to any of claims 5 for monitoring the immune status of a human, characterized in that the monitoring comprises the following steps:
1) isolating peripheral blood mononuclear cells;
2) detecting the number and proportion of lymphocyte subpopulations in the peripheral blood of the sample by a flow cytometer or a mass spectrometer;
3) and determining the immune state of the detection sample according to the quantity and the proportion of the immune cell subsets in the peripheral blood.
9. Use of a kit according to claim 8 for monitoring the immune status of a human, wherein the flow assay preparation of the test sample comprises the steps of:
1) collecting not less than 100 mu L of human peripheral blood as a detection sample; immediately detecting the sample after collection, or refrigerating at 2-8 ℃ and detecting within 48 h;
2) respectively sucking 0.5-20 mu L of 6 reagents from the kit into a flow tube, adding the detection sample into the flow tube, and uniformly mixing the reagents by oscillation to obtain a first pre-sample;
3) incubating the first pre-sample at normal temperature in a dark place for 10-20 min, preferably 15min, or at 2-8 ℃ for 20-40 min, preferably 30min to obtain a second pre-sample;
4) adding 300 mu L-2 mL of erythrocyte lysate into the second pre-sample, oscillating and uniformly mixing, and incubating for 2min at normal temperature in a dark place to obtain a third pre-sample;
5) centrifuging the third pre-sample to obtain a fourth pre-sample; the centrifugation condition of the centrifugation is 500 Xg, normal temperature and 5 min;
6) discarding the supernatant of the fourth pre-sample, and adding PBS buffer solution into the residual sample after discarding the supernatant to carry out resuspension to obtain a detection sample;
7) and (4) detecting the detection sample on a flow cytometer.
10. The use of a kit according to claim 8 for monitoring the immune status of a human, wherein the mass spectrometric preparation of the test sample comprises the steps of:
1) collecting not less than 5mL of peripheral blood of a human body as a detection sample; immediately detecting the sample after collection, or refrigerating at 2-8 ℃ and detecting within 48 h;
2) separating a detection sample by using lymphocyte separating medium to obtain mononuclear cells;
3) counting the cells, taking 1X 106~3×106A cell;
4) using PBS buffer solution to prepare 194Pt (1mM) dead and live staining solution with final concentration of 0.25 mu M, taking 50-1.5 mL of 194Pt dead and live staining solution to resuspend cells, preferably 100 mu L, and staining on ice for 5 min;
5) adding FACS Buffer of 100-1.5 mL, preferably 500 μ L, into each sample, resuspending cells, centrifuging at 2-8 ℃ for 400g/5min, and discarding the supernatant;
6) adding 20-1.5 mL of confining liquid, preferably 50 μ L, into each sample, resuspending the cells, and confining on ice for 20 min-1 h, preferably 20 min;
7) respectively sucking 0.5-20 mu L of 6 metal antibodies from the kit into a centrifugal tube, and adjusting the total volume to 50 mu L by using confining liquid;
8) adding the detection sample into the centrifuge tube, wherein the total volume is 100 mu L, and uniformly mixing the detection sample and the centrifuge tube by oscillation;
9) gently blowing and beating the uniformly mixed cells, and dyeing on ice for 20-60 min, preferably 30 min;
10) adding 1mL of FACS Buffer into each sample, resuspending cells, centrifuging at 2-8 ℃ for 400g/5min, and discarding the supernatant;
11) preparing Ir dye solution with final concentration of 100-500 nM, preferably 250nM, by using Fix and Perm Buffer, taking 200 mu L-1.5 mL of resuspended cells from each sample, and incubating for 1h at room temperature;
12) discarding the supernatant, using 500 mu L-1.5 mL FACS Buffer, preferably 1mL, resuspending the cells, centrifuging at 2-8 ℃ for 800g/5min, discarding the supernatant, resuspending the cells with deionized water, and detecting the detection sample on a mass cytometry.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110413978.0A CN113125719A (en) | 2021-04-16 | 2021-04-16 | 6 antibody kit for monitoring human immune state and application |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110413978.0A CN113125719A (en) | 2021-04-16 | 2021-04-16 | 6 antibody kit for monitoring human immune state and application |
Publications (1)
Publication Number | Publication Date |
---|---|
CN113125719A true CN113125719A (en) | 2021-07-16 |
Family
ID=76777013
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110413978.0A Pending CN113125719A (en) | 2021-04-16 | 2021-04-16 | 6 antibody kit for monitoring human immune state and application |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN113125719A (en) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008249367A (en) * | 2007-03-29 | 2008-10-16 | Biomarker Science:Kk | Evaluation method of immune competence, and kit for evaluating immune competence |
CN108226016A (en) * | 2018-01-12 | 2018-06-29 | 浙江普罗亭健康科技有限公司 | The mass spectrum flow cytometer detection kit of the accurate parting of tumor vaccine cells subgroup |
CN109490544A (en) * | 2018-09-13 | 2019-03-19 | 浙江博真生物科技有限公司 | A kind of kit and its application for detecting the human immunity age |
CN111759864A (en) * | 2020-07-14 | 2020-10-13 | 中国人民解放军总医院 | Application of amniotic fluid stem cells in preparation of medicine for treating lupus nephritis |
-
2021
- 2021-04-16 CN CN202110413978.0A patent/CN113125719A/en active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008249367A (en) * | 2007-03-29 | 2008-10-16 | Biomarker Science:Kk | Evaluation method of immune competence, and kit for evaluating immune competence |
CN108226016A (en) * | 2018-01-12 | 2018-06-29 | 浙江普罗亭健康科技有限公司 | The mass spectrum flow cytometer detection kit of the accurate parting of tumor vaccine cells subgroup |
CN109490544A (en) * | 2018-09-13 | 2019-03-19 | 浙江博真生物科技有限公司 | A kind of kit and its application for detecting the human immunity age |
CN111759864A (en) * | 2020-07-14 | 2020-10-13 | 中国人民解放军总医院 | Application of amniotic fluid stem cells in preparation of medicine for treating lupus nephritis |
Non-Patent Citations (2)
Title |
---|
天津市肿瘤医院: "淋巴细胞亚群检测的临床意义", 《天津市肿瘤医院网站》, pages 1 - 2 * |
强占荣 等: "慢性HBV感染者外周血淋巴细胞亚群及自然杀伤细胞检测的临床意义", 《中国中医药咨讯》, pages 44 - 45 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN113125755A (en) | 9 antibody kit for monitoring human immune state and application thereof | |
Autissier et al. | Immunophenotyping of lymphocyte, monocyte and dendritic cell subsets in normal rhesus macaques by 12-color flow cytometry: clarification on DC heterogeneity | |
CN113125718A (en) | 45 antibody kit for monitoring human immune state and application | |
EP1019546B1 (en) | Methods for measurement of lymphocyte function | |
CN115166252A (en) | Lymphocyte subset grouping and quantitative detection kit, detection method and application thereof | |
Davis et al. | Flow cytometry: clinical applications in equine medicine | |
CN115856302A (en) | Antibody composition for mature B cell tumor immunophenotyping, kit, application and system thereof | |
CN115524490A (en) | HLA-DR + CD14 + CD56 + Use of monocytes for diagnosis in AA or HLH | |
CN113125754A (en) | 23 antibody kit for monitoring human immune state and application | |
CN113125733A (en) | 42 antibody kit for monitoring human immune state and application thereof | |
US20200011865A1 (en) | Methods and kits for detecting basophil activation | |
EP2309260A1 (en) | Method for screening of active tuberculosis | |
CN116482370B (en) | Antibody combination for screening plasma cell tumor treatment target and/or abnormal phenotype and application thereof | |
CN113109575A (en) | 40 antibody kit for monitoring human immune state and application | |
CN117192121A (en) | Antibody composition for MDS and/or AML minimal residual disease detection and application thereof | |
Padmanabhan et al. | Use of the haematopoietic progenitor cell parameter in optimizing timing of peripheral blood stem cell harvest | |
US5968755A (en) | Methods for determining T-cell profiles of immunocompromised subjects | |
CN113125719A (en) | 6 antibody kit for monitoring human immune state and application | |
CN116298275A (en) | NK cell subset of hematophagous lymphocytosis diagnostic marker and application thereof | |
CN114121162B (en) | Method for evaluating immunity | |
Augustine et al. | Comparison of ATP production in whole blood and lymphocyte proliferation in response to phytohemagglutinin | |
CN115290875A (en) | 6-color TBNK lymphocyte subset detection kit and detection method | |
CN112415181A (en) | Basophil degranulation detection kit, detection method and application thereof | |
JP3759412B2 (en) | Use of antibodies for the detection and / or quantification and / or isolation of basophils and / or mast cells and / or their precursor cells and / or their surface structures | |
CN114112868A (en) | Flow cytometry kit for monitoring tumor-related immune microenvironment and monitoring method |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20210716 |